Advances in systemic therapy for HER2-positive metastatic breast cancer

被引:35
|
作者
Morrow, Phuong Khanh H. [1 ]
Zambrana, Francisco [1 ]
Esteva, Francisco J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
来源
BREAST CANCER RESEARCH | 2009年 / 11卷 / 04期
关键词
GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; COST-EFFECTIVENESS ANALYSIS; MULTICENTER PHASE-II; TRASTUZUMAB HERCEPTIN; MONOCLONAL-ANTIBODY; DISEASE PROGRESSION; TUMOR-GROWTH; TYROSINE KINASE; DOSE-ESCALATION;
D O I
10.1186/bcr2324
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human epidermal growth factor receptor (HER) 2 over-expression is associated with a shortened disease-free interval and poor survival. Although the addition of trastuzumab to chemotherapy in the first-line setting has improved response rates, progression-free survival, and overall survival, response rates declined when trastuzumab was used beyond the first-line setting because of multiple mechanisms of resistance. Studies have demonstrated the clinical utility of continuing trastuzumab beyond progression, and further trials to explore this concept are ongoing. New tyrosine kinase inhibitors, monoclonal antibodies, PTEN (phosphatase and tensin homolog) pathway regulators, HER2 antibody-drug conjugates, and inhibitors of heat shock protein-90 are being evaluated to determine whether they may have a role to play in treating trastuzumab-resistant metastatic breast cancer.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] The changing treatment of metastatic her2-positive breast cancer
    Mitsogianni, Maria
    Trontzas, Ioannis P.
    Gomatou, Georgia
    Ioannou, Stephanie
    Syrigos, Nikolaos K.
    Kotteas, Elias A.
    ONCOLOGY LETTERS, 2021, 21 (04)
  • [32] HER2-positive metastatic breast cancer: A changing scenario
    Mustacchi, G.
    Biganzoli, L.
    Pronzato, P.
    Montemurro, F.
    Dambrosio, M.
    Minelli, M.
    Molteni, L.
    Scaltriti, L.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (01) : 78 - 87
  • [33] Overcoming resistance in Her2-positive metastatic breast cancer
    Oksuzoglu, Omur Berna
    LEUKEMIA RESEARCH, 2018, 73 : S13 - S13
  • [34] Adjuvant Therapy for HER2-Positive Breast Cancer
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (12): : 1134 - 1134
  • [35] HER2-Positive Metastatic Breast Cancer: A Comprehensive Review
    Exman, Pedro
    Tolaney, Sara M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 40 - 50
  • [36] Optimizing treatment of HER2-positive metastatic breast cancer
    Jones, AL
    Leyland-Jones, B
    SEMINARS IN ONCOLOGY, 2004, 31 (05) : 29 - 34
  • [37] Advancing outcomes of metastatic HER2-positive breast cancer
    Chumsri, Saranya
    LANCET, 2023, 401 (10390): : 1746 - 1747
  • [38] Margetuximab for the treatment of HER2-positive metastatic breast cancer
    Tarantino, Paolo
    Morganti, Stefania
    Uliano, Jacopo
    Giugliano, Federica
    Crimini, Edoardo
    Curigliano, Giuseppe
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (02) : 127 - 133
  • [39] Targeted Therapy in HER2-Positive Breast Cancer
    Thill, Marc
    Kraft, Clayton
    Friedrich, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (05) : 295 - 302
  • [40] Optimizing the Management of Metastatic HER2-Positive Breast Cancer
    Goel S.
    Tolaney S.
    Current Breast Cancer Reports, 2015, 7 (4) : 190 - 202